Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Huot

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Synapse (New York, N.Y.)|January 7, 2015
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot studyPhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Neurodegenerative Disease Management|July 5, 2025
Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databasesJawad Al-Kassmy, Mohammed Alsalmi, Woojin Kang, et al.
ACS Chemical Neuroscience|May 2, 2017
Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an UpdatePhilippe Huot, Véronique Sgambato-Faure, Susan H Fox, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 26, 2011
Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?Philippe Huot, Susan H Fox, Adrian Newman-Tancredi, et al.
International Review of Neurobiology|March 3, 2023
Metabotropic glutamate receptors in Parkinson's diseaseCynthia Kwan, Woojin Kang, Esther Kim, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 14, 2025
The on-going quest for a long-acting oral form of levodopaMargaux Teil, Jawad Al-Kassmy, Mohammed Alsalmi, et al.
Behavioural Pharmacology|April 2, 2024
Activation of mGlu 2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonismWoojin Kang, Imane Frouni, Cynthia Kwan, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 13, 2017
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasmaFleur Gaudette, Adjia Hamadjida, Dominique Bédard, et al.
Neurology. Genetics|February 19, 2026
Investigating the Genetic Relationship Between Vitamin B12 Metabolism and Parkinson DiseaseRaphael Dering, Margarita Onvumere, Lang Liu, et al.
Neurobiology of Aging|June 22, 2010
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPAPhilippe Huot, Tom H Johnston, Lieke Winkelmolen, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Synapse (New York, N.Y.)|January 7, 2015
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot studyPhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Neurodegenerative Disease Management|July 5, 2025
Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databasesJawad Al-Kassmy, Mohammed Alsalmi, Woojin Kang, et al.
ACS Chemical Neuroscience|May 2, 2017
Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an UpdatePhilippe Huot, Véronique Sgambato-Faure, Susan H Fox, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 26, 2011
Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?Philippe Huot, Susan H Fox, Adrian Newman-Tancredi, et al.
International Review of Neurobiology|March 3, 2023
Metabotropic glutamate receptors in Parkinson's diseaseCynthia Kwan, Woojin Kang, Esther Kim, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 14, 2025
The on-going quest for a long-acting oral form of levodopaMargaux Teil, Jawad Al-Kassmy, Mohammed Alsalmi, et al.
Behavioural Pharmacology|April 2, 2024
Activation of mGlu 2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonismWoojin Kang, Imane Frouni, Cynthia Kwan, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 13, 2017
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasmaFleur Gaudette, Adjia Hamadjida, Dominique Bédard, et al.
Neurology. Genetics|February 19, 2026
Investigating the Genetic Relationship Between Vitamin B12 Metabolism and Parkinson DiseaseRaphael Dering, Margarita Onvumere, Lang Liu, et al.
Neurobiology of Aging|June 22, 2010
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPAPhilippe Huot, Tom H Johnston, Lieke Winkelmolen, et al.
Pageof 11